Schrödinger Inc., 1540 Broadway, New York, New York 10036, United States ...

Results from that study are due next year. Orotomides target the fungal enzyme dihydroorotate dehydrogenase (DHODH), a different mechanism from that of the currently marketed therapies giving them ...

Brequinar is under clinical development by Clear Creek Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...

Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...

Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...

– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin ...

Over the past 30 years, there has been a widespread emergence of resistance to antibiotics in pathogenic bacteria. This resistance is now a serious threat to global public health and could ...

Correspondence to Professor Chunde Bao, Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; baochunde_1678{at}126.com; Professor Liangjing Lu ...